In order to select the most appropriate therapy for patients with advanced gastric cancer, including adenocarcinoma of the EGJ, it is essential to determine the four key criteria: HER2 expression, PD-L1 expression by CPS, Claudin 18.2 status, and microsatellite instability. This evidence concerns the gene ERBB2 and gastric cancer.